BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BC Extra | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

Three women were appointed this week to C-suite positions at biotechs with valuations over $1 billion. The hires come the same week as a report from BIO that found that about 30% of biotech executives...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
BC Extra | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
BC Extra | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc. (NASDAQ:INSM) will begin to search for a successor. It also promoted John Goll to...
BC Extra | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Philip Hampton will step down as chairman ahead of the pharma’s planned split of its consumer healthcare and innovative R&D businesses. The pharma said it has started to search for...
Items per page:
1 - 10 of 369
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

New round pushes Grail’s venture tally over $1.9B Grail Inc. raised $390 million in a series D round, marking the year's largest venture round to date. New backers, including Public Sector Pension Investment Board and...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BC Extra | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

Three women were appointed this week to C-suite positions at biotechs with valuations over $1 billion. The hires come the same week as a report from BIO that found that about 30% of biotech executives...
BC Extra | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

Lonza Group Ltd. (SIX:LONN) CEO Marc Funk will leave the company in January for personal reasons. Chairman Albert Baehny will take on the CEO responsibilities on an interim basis. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) said COO...
BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

Cell therapy company Vericel Corp. (NASDAQ:VCEL) disclosed in an SEC filing that Daniel Orlando resigned as COO on May 28 to become CEO of a private biotech company. SVP, Quality and Regulatory Affairs Michael Halpin...
BC Extra | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of 9.6 million shares at $26. The price is a 7% discount to Insmed's Monday close of $28.07, when...
BC Extra | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc. (NASDAQ:INSM) will begin to search for a successor. It also promoted John Goll to...
BC Extra | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Philip Hampton will step down as chairman ahead of the pharma’s planned split of its consumer healthcare and innovative R&D businesses. The pharma said it has started to search for...
Items per page:
1 - 10 of 369